BPC-157
Body Protection Compound-157
15-amino acid peptide derived from human gastric juice. Promotes tissue repair, gut healing, and angiogenesis. Among the most-researched repair peptides available.
Mechanism of action
Activates VEGF and EGF growth factor pathways, promotes angiogenesis (new blood vessel formation), upregulates nitric oxide synthesis, and modulates the GABAergic system. Accelerates collagen synthesis and tendon-to-bone healing by stimulating tendon fibroblasts.
Effects in the body
BPC-157 acts as a master repair signal throughout the body. It accelerates healing in tendons, ligaments, muscles, and gut lining. Uniquely, it shows systemic effects even when taken orally — one of the few peptides where oral administration reaches therapeutic targets for gut-specific research.
Pros & cons (from the literature)
- Strong tendon and ligament repair data in preclinical models
- Gut healing studied in IBD and leaky gut animal models
- Anti-inflammatory and neuroprotective properties
- Oral AND injectable administration both studied
- Extremely well-tolerated in 300+ animal studies
- No completed Phase III human RCTs
- Theoretical cancer promotion via angiogenesis
- Gray-market purity varies widely (60–85% common vs 98%+ pharmaceutical grade)
- Optimal human dosing not established
- Long-term human safety unknown
Protocol summary (from published research)
Dosing ranges reproduced from published research literature. Not a prescription, not medical advice.
FDA & regulatory status
Evidence base
Sikiric et al. published 300+ papers. Phase I/II trials ongoing as of 2026. No Phase III completion. Extensive preclinical data across multiple tissue types.
Primary research sources
Peer-reviewed literature referenced throughout this profile is drawn from PubMed, Cell Metabolism, and clinical trial registries cited in the evidence base above.
Expert perspective — Dr. Alex Tatem, Urologist
Dr. Alex Tatem is a board-certified Urologist and Men's Health Specialist who has studied peptides for 12 years. Videos featured for educational purposes. ThePeptide.expert is an independent platform.
Dr. Tatem explains BPC-157, TB-500, and the 2026 FDA peptide landscape — including why these compounds were restricted and what the regulatory reversal means for researchers.
Common questions about BPC-157
Is BPC-157 legal in the USA?
BPC-157 is not FDA approved. As of July 2026, the FDA's PCAC voted 8-6 to recommend BPC-157 for the 503A compounding Bulks List — but formal rulemaking is still required before it can be legally compounded by licensed pharmacies. Currently it is available as a research-use-only compound through gray market vendors. See our full regulatory guide for the current status.
What is BPC-157 used for in research?
BPC-157 is primarily studied for tissue repair and healing — tendons, muscles, bones, and gut lining. It has over 300 published papers, the vast majority preclinical animal studies. Three human studies exist as of 2026, none with a proper control group. The tissue repair signal in animals is strong and consistent. Human translation remains the unproven step.
What is the difference between BPC-157 free base and BPC-157 acetate?
Both are forms of the same peptide. The acetate salt form is more stable and more commonly used in research. Free base has slightly higher peptide content by weight. For practical research purposes the difference is minimal — what matters more is the purity and COA documentation from the vendor.
Does BPC-157 cause cancer?
This is a legitimate scientific concern that has not been resolved. BPC-157 stimulates angiogenesis (new blood vessel growth) via VEGF pathways — the same mechanism that tumors use to grow and spread. The cancer risk is theoretically real based on mechanism, but has not been empirically documented in the published literature at research doses. Anyone with a personal or family cancer history should discuss this specifically with a physician.
Have a question about BPC-157 that isn't answered here? Pro members can ask the Expert's Assistant.
Upgrade to Pro to ask →